Literature DB >> 8828503

Lysophosphatidylcholine stimulates interleukin-6 release from rat anterior pituitary cells in vitro.

B L Spangelo1, W D Jarvis.   

Abstract

Interleukin-6 (IL-6) is a B-cell differentiation-inducing cytokine that affects the secretion of several neuroendocrine hormones. Normal rat anterior pituitary (AP) cells synthesize and release IL-6, suggesting a paracrine role for the stimulation of AP hormone release by this cytokine. We have previously reported that IL-1 beta enhances IL-6 release and phospholipase A2 (PLA2)-mediated hydrolysis of phosphatidylcholine (PC) in AP cells. Because lysophosphatidylcholine (LPC) may function as a second messenger for IL-1 beta, we have investigated the effects of exogenous LPC on IL-6 release from AP cells in vitro. AP cells from male Long-Evans rats were dispersed and cultured for 5-6 days in 96-well (100,000 cells/well) culture plates. Cells were rinsed and incubated in the absence or presence of 1.25-40 microM LPC 18:0 (stearoyl) for 6 h, and IL-6 concentrations determined using the 7-TD1 cell bioassay. LPC 18:0 significantly (P < 0.01) stimulated IL-6 release up to 10-fold in a concentration-related manner. In contrast, LPC 18:0 did not affect PRL release. LPC species substituted with progressively shorter saturated 1-acyl chains (16:0-10:0) were less effective for IL-6 induction. Examination of structurally related glycerophospholipid species revealed the specificity of the LPC stimulation of IL-6 release. Thus, 1.25-40 microM lysophosphatidylethanolamine (LPE; 18:0) and lysophosphatidic acid (LPA; 18:0) were without significant effect on AP IL-6 release, demonstrating the specific functional requirement for the phosphorylcholine headgroup. Hydrolysis of the structurally related choline-linked phospholipid sphingomyelin (SM) has been implicated in IL-1 beta action in certain cell types. Similarly, 1.25-20 microM lysosphingomyelin (sphingosylphosphorylcholine; SPC) also significantly (P < or = 0.01) stimulated IL-6 release from AP cells, although SPC exhibited discernibly lower potency and efficacy than LPC. An acyl analog of platelet-activation factor (PAF), i.e. 18:0-2:0 PC (1-stearoyl-2-acetoyl-sn-glycero-3-phosphorylcholine), differs from LPC by an acetyl group in the sn-2 position; PAF was at least as effective as LPC for the stimulation of IL-6 release from AP cells in vitro. Stimulation of IL-6 release by LPC 18:0 was completely suppressed by pharmacological inhibitors of protein kinase C such as H7 (20 microM) and chelerythrine (5 microM). In addition, H7 (20 microM) abolished the stimulation of IL-6 release by IL-1 beta (0.16-100 ng/mL). These findings demonstrate that LPC, acyl PAF, or SPC (but not other lysophospholipids) stimulate IL-6 release from AP cells in vitro. We conclude that LPC-mediated activation of protein kinase C is involved in the stimulatory actions of IL-1 beta in AP cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8828503     DOI: 10.1210/endo.137.10.8828503

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  11 in total

1.  Methylmercury-induced IL-6 release requires phospholipase C activities.

Authors:  Jason Y Chang
Journal:  Neurosci Lett       Date:  2011-04-12       Impact factor: 3.046

2.  Lysophosphatidylcholine induces inflammatory activation of human coronary artery smooth muscle cells.

Authors:  Nambi Aiyar; Jyoti Disa; Zhaohui Ao; Haisong Ju; Sandhya Nerurkar; Robert N Willette; Colin H Macphee; Douglas G Johns; Stephen A Douglas
Journal:  Mol Cell Biochem       Date:  2006-08-08       Impact factor: 3.396

3.  Activation of lipid metabolism contributes to interleukin-8 production during Chlamydia trachomatis infection of cervical epithelial cells.

Authors:  Elaine Y Fukuda; Sonya P Lad; David P Mikolon; Milena Iacobelli-Martinez; Erguang Li
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

4.  IL-6 release from mouse glia caused by MeHg requires cytosolic phospholipase A2 activation.

Authors:  Jason Y Chang; Pao-Feng Tsai
Journal:  Neurosci Lett       Date:  2009-06-17       Impact factor: 3.046

5.  Bioactive lysophosphatidylcholine 16:0 and 18:0 are elevated in lungs of asthmatic subjects.

Authors:  Mark Yoder; Yan Zhuge; Yang Yuan; Oksana Holian; Sherry Kuo; Richard van Breemen; Larry L Thomas; Hazel Lum
Journal:  Allergy Asthma Immunol Res       Date:  2013-12-05       Impact factor: 5.764

6.  Stimulated bronchial epithelial cells release bioactive lysophosphatidylcholine 16:0, 18:0, and 18:1.

Authors:  Yan Zhuge; Yang Yuan; Richard van Breemen; Michael Degrand; Oksana Holian; Mark Yoder; Hazel Lum
Journal:  Allergy Asthma Immunol Res       Date:  2013-11-28       Impact factor: 5.764

7.  Oxidized lipids and lysophosphatidylcholine induce the chemotaxis, up-regulate the expression of CCR9 and CXCR4 and abrogate the release of IL-6 in human monocytes.

Authors:  Johannes Rolin; Heidi Vego; Azzam A Maghazachi
Journal:  Toxins (Basel)       Date:  2014-09-23       Impact factor: 4.546

8.  Lysophosphatidylcholine Induces NLRP3 Inflammasome-Mediated Foam Cell Formation and Pyroptosis in Human Monocytes and Endothelial Cells.

Authors:  Rafael Corrêa; Luís Felipe Fonseca Silva; Dalila Juliana Silva Ribeiro; Raquel das Neves Almeida; Igor de Oliveira Santos; Luís Henrique Corrêa; Lívia Pimentel de Sant'Ana; Leonardo Santos Assunção; Patrícia T Bozza; Kelly Grace Magalhães
Journal:  Front Immunol       Date:  2020-01-09       Impact factor: 7.561

9.  Mortality prediction in patients with severe septic shock: a pilot study using a target metabolomics approach.

Authors:  Manuela Ferrario; Alice Cambiaghi; Laura Brunelli; Silvia Giordano; Pietro Caironi; Luca Guatteri; Ferdinando Raimondi; Luciano Gattinoni; Roberto Latini; Serge Masson; Giuseppe Ristagno; Roberta Pastorelli
Journal:  Sci Rep       Date:  2016-02-05       Impact factor: 4.379

Review 10.  Targeting Lysophosphatidic Acid in Cancer: The Issues in Moving from Bench to Bedside.

Authors:  Yan Xu
Journal:  Cancers (Basel)       Date:  2019-10-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.